CIENCIASMEDICASNEWS: Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial - The Lancet Respiratory Medicine

sábado, 25 de marzo de 2023

Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial - The Lancet Respiratory Medicine

Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial - The Lancet Respiratory Medicine

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)